Effectiveness and safety of orelabrutinib with rituximab and lenalidomide in low KPS score and elderly patients with newly diagnosed primary central nervous system lymphoma—a single-center retrospective study

被引：0
|
作者：
Xiao-Ling Guo
Zi-Yu Zhao
Xue-Fei Guo
Ya-Bei Zuo
Jin-Ao Li
Zi-Yuan Nie
Jin-Hai Ren
机构：
[1] The Second Hospital of Hebei Medical University,Department of Hematology
来源：
Neurological Sciences | 2024年 / 45卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2931 / 2934
页数：3
相关论文
共 50 条
  • [31] Preliminary Results of Penpulimab Combined with RMA (rituximab, methotrexate, and cytarabine) for Newly Diagnosed Primary Central Nervous System Lymphoma
    Shen, Haorui
    Wu, Jia-Zhu
    Liang, Jin-Hua
    Yin, Hua
    Wang, Li
    Li, Jianyong
    Xu, Wei
    BLOOD, 2022, 140 : 3821 - 3822
  • [32] Central nervous system relapse in non-Hodgkin lymphoma - A single-center study of 532 patients
    Bollen, ELEM
    Brouwer, RE
    Hamers, S
    Hermans, J
    Kluin, PM
    Sankatsing, SUC
    ATjak, RV
    Charvat, MV
    KluinNelemans, JC
    ARCHIVES OF NEUROLOGY, 1997, 54 (07) : 854 - 859
  • [33] Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial
    Zhang, Yan
    Wang, Wei
    Li, Jian
    Zhou, Daobin
    Zhang, Wei
    Zhao, Danqing
    Wei, Chong
    Zhang, Lu
    Cao, Xinxin
    BLOOD, 2022, 140 : 6608 - 6609
  • [34] Infectious disease consultations and newly diagnosed cancer patients A single-center retrospective observational study
    Hadano, Yoshiro
    Watari, Takashi
    Yasunaga, Hiroshi
    MEDICINE, 2020, 99 (25) : E20876
  • [35] Tumor Vascular Permeability Pattern Is Associated With Complete Response in Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Retrospective Cohort Study
    Chung, Sae Rom
    Choi, Young Jun
    Kim, Ho Sung
    Park, Ji Eun
    Shim, Woo Hyun
    Kim, Sang Joon
    MEDICINE, 2016, 95 (06)
  • [36] Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
    Xianggui Yuan
    Teng Yu
    Yurong Huang
    Huawei Jiang
    Xiaohua Xu
    Yun Liang
    Wenbin Qian
    Scientific Reports, 12 (1)
  • [37] Rituximab with high-dose methotrexate is effective and cost-effective in newly diagnosed primary central nervous system lymphoma
    Yuan, Xianggui
    Yu, Teng
    Huang, Yurong
    Jiang, Huawei
    Xu, Xiaohua
    Liang, Yun
    Qian, Wenbin
    SCIENTIFIC REPORTS, 2022, 12 (01):
  • [38] Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients
    Kim, Jinuk
    Kim, Tae Gyu
    Lee, Hyoun Wook
    Kim, Seok Hyun
    Park, Ji Eun
    Lee, Moonok
    Kim, Young Zoon
    CURRENT ONCOLOGY, 2021, 28 (06) : 4655 - 4672
  • [39] Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients
    Birsen, Rudy
    Willems, Lise
    Pallud, Johan
    Blanc, Estelle
    Burroni, Barbara
    Legoff, Marielle
    Le Ray, Emmanuelle
    Pilorge, Sylvain
    Deau, Benedicte
    Franchi, Patricia
    Vignon, Marguerite
    Kirova, Yioula
    Edjlali, Myriam
    Houillier, Caroline
    Soussain, Carole
    Varlet, Pascale
    Dezamis, Edouard
    Damotte, Diane
    Bouscary, Didier
    Tamburini, Jerome
    HAEMATOLOGICA, 2018, 103 (07) : E296 - E299
  • [40] A retrospective study of the safety and efficacy of rituximab in Iranian patients with myasthenia gravis: A single-center experience
    Ziaadini, Bentolhoda
    Karimi, Narges
    Panahi, Akram
    Okhovat, Ali Asghar
    Fatehi, Farzad
    Nafissi, Shahriar
    CURRENT JOURNAL OF NEUROLOGY, 2022, 21 (02): : 91 - 97
12345